$TYRA News

Tyra Biosciences (TYRA) Stock Looks Expensive Against Its Book Value

Here's Why Tyra Biosciences (TYRA) is Poised for a Turnaround After Losing 27% in 4 Weeks

Oppenheimer Reiterates Outperform on Tyra Biosciences, Lowers Price Target to $40

HC Wainwright & Co. Maintains Buy on Tyra Biosciences, Lowers Price Target to $29

Tyra Biosciences (TYRA) Dabogratinib Delivers 57% Complete Response Rate in Phase 2 Trial. Is Phase 3 Supported?

Tyra Biosciences (TYRA) Stock May Be Priced Too Richly For Its Assets

Tyra Announces Pricing of $400 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Tyra Biosciences Prices Underwritten Offering Of 9,079,000 Shares And Warrants At $22.03 Per Unit

Tyra Biosciences Files Prospectus To Sell Mixed Securities Shelf Of Undisclosed Amount

Tyra Biosciences, Inc. (TYRA) Discusses Initial SURF302 Results on Oral Dabogratinib for Intermediate Risk NMIBC Transcript

Tyra Biosciences, Inc. (TYRA) Discusses Initial SURF302 Results on Oral Dabogratinib for Intermediate Risk NMIBC - Slideshow

Wedbush Reiterates Outperform on Tyra Biosciences, Maintains $53 Price Target

HC Wainwright & Co. Maintains Buy on Tyra Biosciences, Lowers Price Target to $30

Tyra Plummets To 10-Month Low On Mixed Cancer Test; Why Analysts Are Upbeat

Tyra disappoints investors with bladder cancer data

Tyra Biosciences shares plunge 30% after Phase 2 dabogratinib data

Tyra Biosciences Tanks As IR NMIBC Data Disappoints: I'm Firmly On The Sidelines

Why Is Tyra Biosciences Stock Sinking Wednesday?

Tyra Biosciences Reports Initial Phase 2 SURF302 Results Supporting the First Potential Oral Innovation in LG IR NMIBC with Dabogratinib

Tyra Biosciences to Present at the Cantor Global Healthcare Conference